Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). II. Local skin tolerability

Maturitas

Volumn 25, Issue 3, 1996, Pages 175-185

  Rozenbaum, Henri ^a   Birkhäuser, Martin ^b   De Nooyer, Coenraad ^c   Lambotte, René ^d   Pornel, Bruno ^a   Schneider, Hermann ^e   Studd, John ^f   Thebault, Jean ^g  

^a Hopital Univ de Gynecologie et d'O ^*  (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c Infection and Immunology   (Netherlands)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f LISTER HOSPITAL   (United Kingdom)

^g Hopital de la Fondation Cognacq Jay   (France)

Author keywords

estradiol; HRT; menopause; skin tolerability; transdermal

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN IRRITATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; CLIMACTERIC; DRUG ERUPTIONS; DRUG MONITORING; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030296166     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01074-2     Document Type: Article

References (13)

1. [1] De Lignières B, Basdevant A, Thomas G et al. Biological effects of estradiol 17β in post-menopausal women: oral versus percutaneous administration. J Clin Endocrinol Metabol 1986; 62: 536-541.
2. [2] Faguer de Moustier B, Conard J, Guyene TT et al. Comparative metabolic study of percutaneous versus oral micronized 17β estradiol in replacement therapy. Maturitas 1989; 11: 275-286.
3. [3] Judd HL, Cleary RE, Creasman WT, et al. Estrogen replacement therapy. Am J Obstet Gynecol 1981; 58: 267-275.
4. [4] Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
5. [5] Estraderm®. Full prescribing information. Physician's Desk Reference, 1993.
6. [6] Padwick ML, Endacott J, Whitehead MI. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-1091.
7. [7] Place VA, Powers M, Darley PE et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of post-menopausal symptoms. Am J Obstet Gynecol 1985; 152: 1092-1099.
8. [8] Rozenbaum H, Birkhauser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, Studd J. Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy. Maturitas (this issue).
9. [9] Davis GF, Winter L. Cumulative irritation study of placebo transdermal estrogen patches. Curr Ther Res 1987; 42: 712-719.
10. [10] Corson SL. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. Int J Fertil 1993; 38: 36-44.
11. [11] Van Leusden HAIM, Albertyn G, Verlaine C, Van Ruymbeke J. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Int J Fertil 1993; 38: 210-218.
12. [12] Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandepol C. Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 1995; 22: 207-218.
13. [13] McBurney EI, Noel SB, Collins JH. Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 1989; 20: 508-510.